Protagonist Therapeutics Inc PTGX:NASDAQ

Last Price$16.57NASDAQ Previous Close - Last Trade as of 4:00PM ET 2/08/23

Today's Change+0.74(4.67%)
Bid (Size)$16.08 (4)
Ask (Size)$16.49 (4)
Day Low / High$15.64 - 16.85
Volume2.0 M
 

View Biotechnology IndustryPeer Comparison as of 02/08/2023

 

Protagonist Therapeutics Inc ( NASDAQ )

Price: $16.57
Change: +0.74 (4.67%)
Volume: 2.0 M
4:00PM ET 2/08/2023
 
 

Editas Medicine Inc ( NASDAQ )

Price: $10.34
Change: -0.88 (7.84%)
Volume: 1.6 M
4:00PM ET 2/08/2023
 
 

ANI Pharmaceuticals Inc ( NASDAQ )

Price: $44.85
Change: -0.87 (1.90%)
Volume: 53.8 K
4:00PM ET 2/08/2023
 
 

Alector Inc ( NASDAQ )

Price: $9.36
Change: -0.38 (3.90%)
Volume: 519.7 K
4:00PM ET 2/08/2023
 
 

Altimmune Inc ( NASDAQ )

Price: $13.85
Change: -1.32 (8.70%)
Volume: 1.1 M
4:00PM ET 2/08/2023
 

Read more news Recent News

--HC Wainwright Lowers Price Target on Protagonist Therapeutics to $33 From $50, Maintains Buy Rating
9:40AM ET 11/10/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

JMP Securities Reinstates Protagonist Therapeutics at Market Outperform With $21 Price Target
6:01AM ET 8/25/2022 MT Newswires

Protagonist Therapeutics (PTGX) has an average rating of outperform and price targets ranging from $21 to $50, according to analysts polled by Capital IQ....

Piper Sandler Adjusts Price Target on Protagonist Therapeutics to $35 From $60, Reiterates Overweight Rating
6:52AM ET 5/18/2022 MT Newswires

Protagonist Therapeutics (PTGX) has an average rating of buy and price targets ranging from $30 to $60, according to analysts polled by Capital IQ. (MT...

--SVB Leerink Adjusts Protagonist Therapeutics' Price Target to $30 from $50, Keeps Outperform Rating
10:00AM ET 5/05/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Company Profile

Business DescriptionProtagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA. View company web site for more details
Address7707 Gateway Boulevard
Newark, California 94560-1160
Phone+1.510.474.0170
Number of Employees64
Recent SEC Filing01/31/2023SC 13G/A
President, Chief Executive Officer & DirectorDinesh V. Patel
Chief Financial Officer & Executive Vice PresidentAsif Ali
Vice President-TechnologyMark L. Smythe
Chief Medical OfficerSamuel R. Saks

Company Highlights

Price Open$15.83
Previous Close$15.83
52 Week Range$6.91 - 29.25
Market Capitalization$815.2 M
Shares Outstanding49.2 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement02/27/2023

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.67
Beta vs. S&P 500N/A
Revenue$30.9 M
Net Profit Margin-369.64%
Return on Equity-46.74%

Analyst Ratings as of 12/09/2022

Buy
6
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset